---
title: How I individualize selection of JAK inhibitors for patients with myelofibrosis
date: '2024-10-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39357058/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20241003195203&v=2.18.0.post9+e462414
source: Blood
description: The advent of JAK inhibitors (JAKi) inaugurated a novel era in the treatment
  of myelofibrosis (MF), a myeloproliferative neoplasm with heterogeneous clinical
  manifestations. Four JAKi have been approved for intermediate or high-risk MF, in
  the US. Regulatory approval of the first JAK1/2 inhibitor, ruxolitinib, in 2011
  transformed the landscape of MF by markedly controlling splenomegaly and constitutional
  symptoms, improving patients' lives, and prolonging survival. Fedratinib, the ...
disable_comments: true
---
The advent of JAK inhibitors (JAKi) inaugurated a novel era in the treatment of myelofibrosis (MF), a myeloproliferative neoplasm with heterogeneous clinical manifestations. Four JAKi have been approved for intermediate or high-risk MF, in the US. Regulatory approval of the first JAK1/2 inhibitor, ruxolitinib, in 2011 transformed the landscape of MF by markedly controlling splenomegaly and constitutional symptoms, improving patients' lives, and prolonging survival. Fedratinib, the ...